Evidence map›Paper›PMID 40428231›Full record

ArticleDiagnostics (Basel, Switzerland)2025

Predicting Clinical Response to Monoclonal TNF Inhibitors in Rheumatoid Arthritis: A Transcriptomic Approach Based on Transmembrane TNF Reverse Signaling and Nrf2 Activation.

Katy Diallo, Yannick Degboé, Michel Baron, Anaïs Bellin-Robert, Jean-Frédéric Boyer, Adeline Ruyssen-Witrand, Arnaud Constantin, Benjamin Rauwel, Alain Cantagrel, Jean-Luc Davignon

Abstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Katy DialloInstitut Toulousain des Maladies Infectieuses et Inflammatoires (INFINITY), INSERM UMR1291, 31024 Toulouse, France.ORCID 0009-0009-5488-7333
Yannick DegboéInstitut Toulousain des Maladies Infectieuses et Inflammatoires (INFINITY), INSERM UMR1291, 31024 Toulouse, France.
Michel BaronInstitut Toulousain des Maladies Infectieuses et Inflammatoires (INFINITY), INSERM UMR1291, 31024 Toulouse, France.
Anaïs Bellin-RobertInstitut Toulousain des Maladies Infectieuses et Inflammatoires (INFINITY), INSERM UMR1291, 31024 Toulouse, France.
Jean-Frédéric BoyerFaculty of Health, CHU Toulouse, University of Toulouse, 31059 Toulouse, France.
Adeline Ruyssen-WitrandFaculty of Health, CHU Toulouse, University of Toulouse, 31059 Toulouse, France.
Arnaud ConstantinInstitut Toulousain des Maladies Infectieuses et Inflammatoires (INFINITY), INSERM UMR1291, 31024 Toulouse, France.
Benjamin RauwelInstitut Toulousain des Maladies Infectieuses et Inflammatoires (INFINITY), INSERM UMR1291, 31024 Toulouse, France.
Alain CantagrelFaculty of Health, CHU Toulouse, University of Toulouse, 31059 Toulouse, France.ORCID 0000-0001-8890-9099
Jean-Luc DavignonFaculty of Health, CHU Toulouse, University of Toulouse, 31059 Toulouse, France.

Funding

MSD AVENIR "BIORIC"Région Occitanie Prematuration Program
6 · The paper itself

Abstract

(1)

Indexed as

anti-TNFbiotherapymonoclonal antibodiesmonocytesNrf2predictionreverse signalingrheumatoid arthritis

Identifiers

PMID40428231
PMCPMC12109967

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.